Varicella zoster virus reactivation reported with isatuximab use.

Isatuximab is a CD38-directed antibody indicated for the treatment of relapsed or refractory multiple myeloma. The Division of Pharmacovigilance at the U.S.

Association of Daratumumab Use With Ocular Events in a Case Series of US Adults.

This case series uses postmarketing data to evaluate the association of daratumumab use with ocular events such as acute angle-closure glaucoma, myopic shift, and choroidal effusions among US adults.

Postmarketing Cases of Enfortumab Vedotin-Associated Skin Reactions Reported as Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis.

This case series study uses data from the FDA Adverse Event Reporting System to investigate a potential association between enfortumab vedotin treatment and Stevens-Johnson Syndrome and toxic epidermal necrolysis.

Arterial aneurysm and dissection with systemic vascular endothelial growth factor inhibitors: A review of cases reported to the FDA Adverse Event Reporting System and published in the literature.

The US Food and Drug Administration (FDA) has approved multiple systemic vascular endothelial growth factor (VEGF) inhibitors since 2004 to treat various malignancies. Inhibition of the VEGF signaling pathway can result in impairment of vascular wall integrity through medial degeneration and endothelial dysfunction, potentially resulting in arterial (including aortic) aneurysm/dissection. We performed a postmarketing review to evaluate arterial aneurysm/dissection as a potential safety risk for patients with cancer treated with VEGF inhibitors.